Global Osteoporosis Drugs Market Research Report - Forecast to 2022

Report / Search Code: MRFR/Pharma/1841-HCRR
Publish Date: May, 2019

Price

<table>
<thead>
<tr>
<th>1-user PDF</th>
<th>$4450.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enterprise PDF</td>
<td>$6250.0</td>
</tr>
</tbody>
</table>

Description:

Global Osteoporosis Drugs Market Information, by drug class (Bisphosphonates, Calcitonins, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone (PTH) and Others), by route of administration (oral, injectable and others) and by gender (male and female) - Forecast to 2022

Market Synopsis of Global Osteoporosis Drugs Market:

Market Scenario:
Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis. The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.

The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.

The market restraints are loss of patents of block busters, greater penetration of generics and fragmentation of market, poor efficacy and side effects of present therapies, non-life threatening nature and poor symptoms of osteoporosis etc.

Taking all the factors into consideration, we expect the global osteoporosis market which totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a CAGR of 4.7%.

Study Objectives Global Osteoporosis Drugs Market:

- To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global osteoporosis drugs market
- To provide insights about factors affecting the market growth
- To analyze the market based on various factors-price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries-Americas, Europe, Asia-Pacific, and Middle East & Africa.
- To provide country level analysis of the market with respect to the current market size and future prospective
- To provide country level analysis of the market for segments by drug class (bisphosphonates, calcitonins, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others), by route of administration (oral, injectable and others) and by gender (male, female and children).
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.

Global Osteoporosis Drugs Market, by Route of Administration, 2015 (%):

Key Players for Global Osteoporosis Drugs Market:
Some of the key players in this market are: Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others.

Segments:
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.

Intended Audience:
- Osteoporosis Drugs Manufacturers
- Osteoporosis Drugs Suppliers
- Private Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Government Research Laboratories
- Contract Manufacturing Organizations

Regional Analysis of Global Osteoporosis Drugs Market:
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.

The report for Global Osteoporosis Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure

2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research

3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators

4 Market Factor Analysis
4.1 Porter’s five forces model
4.1.1 Bargaining Power of suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants

5 Global Osteoporosis Drugs market, by Drug Class
5.1 Introduction
5.2 Bisphosphonates
5.3 Calcitonins
5.4 Selective Estrogen Receptor Modulators (SERMs)
5.5 Parathyroid Hormone (PTH)
5.6 Others

6 Global Osteoporosis Drugs Market, By Route of Administration
6.1 Introduction
6.2 Oral
6.3 Injectable
6.4 Others

7 Global Osteoporosis Drugs Market, By Gender
7.1 Introduction
7.2 Male
7.3 Female

8 Global Osteoporosis Drugs market, by Regions
8.1 Introduction
8.1.1 Americas
8.1.1.1 North America
8.1.1.2 South America
8.1.2 Europe
8.1.2.1 Germany
8.1.2.2 France
8.1.2.3 UK
8.1.2.4 Italy
10.6.2 Product/Business Segment Overview
10.6.3 Financials
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Novo Nordisk
10.7.1 Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.7 Teva Pharmaceutical Industries Ltd.
10.7.1 Overview
10.7.2 Product/Business Segment Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.7 Teva Pharmaceutical Industries Ltd.
10.8 Others
10.8.1 Overview
10.8.2 Product/Business Segment Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
11 Others
12 Appendix

List of Tables
TABLE 1 GLOBAL OSTEOPOROSIS DRUGS MARKET, 2013-2022 (USD MILLION)
TABLE 2 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS, 2013-2022 (USD MILLION)
TABLE 3 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2013-2022 (USD MILLION)
TABLE 4 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY GENDER, 2013-2022 (USD MILLION)
TABLE 5 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION, 2013-2022 (USD MILLION)

List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS
FIGURE 4 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
FIGURE 5 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY GENDER
FIGURE 6 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION
FIGURE 7 GLOBAL OSTEOPOROSIS DRUGS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)